Business Context and Reporting Period
Scilex Holding Company filed this Form 8-K on February 26, 2024, regarding a settlement term sheet resolving litigation involving its wholly owned subsidiary, Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc., and Virpax Pharmaceuticals, Inc. The filing does not report quarterly or annual operating results.
Material Agreement and Financial Terms
- Virpax agreed to pay Scilex $3.5 million by March 1, 2024.
- Virpax agreed to pay an additional $2.5 million by July 1, 2024.
- If specified drug candidates are sold, Virpax will pay royalties on annual net sales of 6% for each of Epoladerm, Probudur, and Envelta, subject to termination upon expiration of applicable patent rights and regulatory exclusivity.
- The term sheet requires Virpax to remove and destroy the Company’s nonpublic information from its systems and hard copies, while retaining a preservation copy until the litigation is fully resolved.
Litigation Status and Changes
Scilex Pharma and Sorrento filed the Delaware Court of Chancery action in March 2021 against Anthony Mack, a former Scilex Pharma president, and Virpax. The claims included breach of restrictive covenants, fiduciary-duty violations, tortious interference, aiding and abetting, and trade-secret misappropriation.
Following a September 2023 trial decision largely favorable to the plaintiffs, the parties briefed remedies. Scilex Pharma, Sorrento, and Virpax entered into the settlement term sheet on February 26, 2024. The plaintiffs’ release applies only to Virpax and is conditioned on Virpax making the initial $3.5 million payment. Claims against Mr. Mack remain ongoing.
Guidance, Outlook, Risks, and Unusual Items
- The parties intended to execute a definitive settlement agreement by March 1, 2024. If they did not, the term sheet would become binding and enforceable on its stated terms.
- Future royalty proceeds are contingent on the sale of the specified drug candidates and therefore are not assured.
- The filing does not provide guidance on revenue, earnings, cash flow, margins, debt, liquidity, or the accounting treatment of the settlement proceeds.
- Key contingencies include receipt of the scheduled payments, completion of the definitive settlement documentation, and continued litigation against Mr. Mack.
Important Facts to Verify
- Whether the $3.5 million initial payment was received by March 1, 2024.
- Whether the definitive settlement agreement was executed and whether the $2.5 million payment was made by July 1, 2024.
- How Scilex recorded the settlement payments and any related legal or contingent-royalty amounts in subsequent financial statements.
- The status and potential outcome of the remaining claims against Anthony Mack.
- Whether Epoladerm, Probudur, or Envelta generate sales that could trigger royalty payments.